valine and Erdheim-Chester Disease

valine has been researched along with Erdheim-Chester Disease in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abdel-Wahab, O; Arcila, ME; Baselga, J; Blay, JY; Chau, I; Diamond, EL; Durham, B; Elez, E; Erinjeri, JP; Hyman, DM; Lacouture, M; Lockhart, AC; Makrutzki, M; Martínez-Valle, F; Pitcher, B; Puzanov, I; Raje, NS; Riehl, T; Subbiah, V; Torrisi, J; Ulaner, G; Wolf, J	1
Amoura, Z; Arnaud, L; Barete, S; Benameur, N; Besnard, S; Charlotte, F; Cluzel, P; Cohen-Aubart, F; Donadieu, J; Drier, A; Emile, JF; Graffin, B; Granel, B; Grenier, PA; Haroche, J; Hervier, B; Idbaih, A; Lifermann, F; Maksud, P; Ory, JP; Tolédano, D	1
Blombery, P; Lade, S; Prince, HM; Wong, SQ	1
Amoura, Z; Arnaud, L; Benameur, N; Besnard, S; Charlotte, F; Cluzel, P; Cohen-Aubart, F; Donadieu, J; Drier, A; Emile, JF; Haroche, J; Hervier, B; Maksud, P	1

Trials

2 trial(s) available for valine and Erdheim-Chester Disease

Article	Year
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA oncology, 2018, Mar-01, Volume: 4, Issue:3 Topics: Aged; Amino Acid Substitution; Erdheim-Chester Disease; Female; Fluorodeoxyglucose F18; Histiocytosis, Langerhans-Cell; Humans; Male; Middle Aged; Mutation, Missense; Positron Emission Tomography Computed Tomography; Prognosis; Proto-Oncogene Proteins B-raf; Survival Analysis; Treatment Outcome; Valine; Vemurafenib	2018
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Feb-10, Volume: 33, Issue:5 Topics: Adult; Aged; Erdheim-Chester Disease; Female; Fluorodeoxyglucose F18; Glutamic Acid; Humans; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Radiopharmaceuticals; Skin; Sulfonamides; Treatment Outcome; Valine; Vemurafenib	2015

Article

Year

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

JAMA oncology, 2018, Mar-01, Volume: 4, Issue:3

Topics: Aged; Amino Acid Substitution; Erdheim-Chester Disease; Female; Fluorodeoxyglucose F18; Histiocytosis, Langerhans-Cell; Humans; Male; Middle Aged; Mutation, Missense; Positron Emission Tomography Computed Tomography; Prognosis; Proto-Oncogene Proteins B-raf; Survival Analysis; Treatment Outcome; Valine; Vemurafenib

2018

Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Feb-10, Volume: 33, Issue:5

Topics: Adult; Aged; Erdheim-Chester Disease; Female; Fluorodeoxyglucose F18; Glutamic Acid; Humans; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Radiopharmaceuticals; Skin; Sulfonamides; Treatment Outcome; Valine; Vemurafenib

2015

Other Studies

2 other study(ies) available for valine and Erdheim-Chester Disease

Article	Year
Erdheim-Chester disease harboring the BRAF V600E mutation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Erdheim-Chester Disease; Glutamic Acid; Humans; Imatinib Mesylate; Immunohistochemistry; Interferon-alpha; Male; Middle Aged; Mutation; Piperazines; Prednisolone; Proto-Oncogene Proteins B-raf; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Valine	2012
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood, 2013, Feb-28, Volume: 121, Issue:9 Topics: Adult; Aged; Amino Acid Substitution; Anti-Inflammatory Agents; Drug Resistance; Erdheim-Chester Disease; Female; Glutamic Acid; Histiocytosis, Langerhans-Cell; Humans; Indoles; Male; Middle Aged; Mutation, Missense; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; Valine; Vemurafenib	2013

Article

Year

Erdheim-Chester disease harboring the BRAF V600E mutation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32

Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Erdheim-Chester Disease; Glutamic Acid; Humans; Imatinib Mesylate; Immunohistochemistry; Interferon-alpha; Male; Middle Aged; Mutation; Piperazines; Prednisolone; Proto-Oncogene Proteins B-raf; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Valine

2012

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.

Blood, 2013, Feb-28, Volume: 121, Issue:9

Topics: Adult; Aged; Amino Acid Substitution; Anti-Inflammatory Agents; Drug Resistance; Erdheim-Chester Disease; Female; Glutamic Acid; Histiocytosis, Langerhans-Cell; Humans; Indoles; Male; Middle Aged; Mutation, Missense; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; Valine; Vemurafenib

2013